The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
By Steven M. Teutsch, Linda A. Bradley, G. Palomaki, James E. Haddow, M. Piper, N. Calonge, W. Dotson, M. P. Douglas, Alfred O. Berg. Genetics in Medicine, 2009
685 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Genetics, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/e9f812b69d83c0441efb0fe4cf1493f06dd3e0f8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
In Genetics
Citations in the corpus
- Returning Individual Research Results to Participants: Guidance for a New Research Paradigm (2018, background): “…it can provide information that can be used to inform patient–clinician decisions regarding the prevention, management, or treatment of a disease or health condition—and, in particular, information that would be expected to yield measurable improvement in clinical outcomes (Teutsch et al., 2009).”
- Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011, methodology): “Methodological Issues in Ki67 Measurement: Analytical Validity The above scenarios highlighting areas in which Ki67 measurement may well have clinical utility prompt a need for reproducible methodology and consistent scoring methods; in other words, the analytical validity, as defined by Evaluation ”
- American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. (2010, background): “Clinical validity means that data exist regarding how accurately a test reflects a patient’s clinical status (eg, being at increased risk for cancer).(21) In 2001, the US Department of Health and Human Services Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) recommended that ”
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, neutral): “compared with treatment of the patient in the absence of the biomarker test result.(8,9,13) Benefits may include improvement in survival end points such as event-free survival, DFS, progressionfree survival, or OS.”
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020, neutral): “” (14) A similar definition was adopted by the National Academy of Medicine (16).”